RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q2 2024
Top Holdings68 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MADRIGAL PHARMACEUTICALS INC | 1.9M | $536.7M | 8.3% | $267.51 | +4.73% | 5 qtrssince 2023-Q2 | Increased 98 |
ROCKET PHARMACEUTICALS INC | 17.7M | $380.8M | 5.9% | $18.79 | +14.56% | 22 qtrssince 2019-Q1 | Unchanged 0 |
AXSOME THERAPEUTICS INC | 4.6M | $373.1M | 5.8% | $62.01 | +29.81% | 22 qtrssince 2019-Q1 | Increased 62 |
| 8.8M | $359.8M | 5.6% | $25.64 | +59.33% | 17 qtrssince 2020-Q2 | Increased 67 | |
ARGENX SE - ADR | 654,430 | $281.4M | 4.4% | $348.48 | +23.41% | 22 qtrssince 2019-Q1 | Decreased 0 |
NATERA INC | 2.6M | $280.8M | 4.3% | $42.12 | +157.13% | 20 qtrssince 2019-Q3 | Unchanged 0 |
MERUS N V | 4.2M | $246.7M | 3.8% | $34.06 | +73.74% | 5 qtrssince 2023-Q2 | Increased 57 |
INSMED INC | 3.6M | $243.9M | 3.8% | $44.25 | +51.40% | 5 qtrssince 2023-Q2 | Increased 90 |
PTC THERAPEUTICS INC | 7.4M | $226.1M | 3.5% | $43.39 | -29.52% | 22 qtrssince 2019-Q1 | Decreased 0 |
DYNE THERAPEUTICS INC | 6.4M | $225.4M | 3.5% | $31.95 | +10.45% | 2 qtrssince 2024-Q1 | Increased 91 |
ACADIA Pharmaceuticals Inc. | 13.7M | $222.7M | 3.4% | $18.35 | -11.44% | 9 qtrssince 2022-Q2 | Decreased 0 |
BRUKER CORP | 3.4M | $219.8M | 3.4% | $72.35 | -12.39% | 6 qtrssince 2023-Q1 | Increased 58 |
MASIMO CORP | 1.5M | $184.2M | 2.9% | $174.28 | -27.74% | 22 qtrssince 2019-Q1 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.3M | $183.2M | 2.8% | $22.38 | +54.80% | 20 qtrssince 2019-Q3 | Decreased 0 |
ALKERMES PLC | 7.1M | $170.1M | 2.6% | $27.05 | -10.91% | 4 qtrssince 2023-Q3 | Increased 60 |
IMMUNOCORE HLDGS PLC | 4.9M | $165M | 2.6% | $43.05 | -21.28% | 14 qtrssince 2021-Q1 | Decreased 0 |
CYTOKINETICS INC | 2.7M | $147.4M | 2.3% | $28.96 | +87.08% | 16 qtrssince 2020-Q3 | Increased 56 |
Ultragenyx Pharmaceutical, Inc. | 3.3M | $134M | 2.1% | $52.92 | -22.33% | 11 qtrssince 2021-Q4 | Decreased 0 |
PENUMBRA INC | 742,105 | $133.6M | 2.1% | $254.83 | -29.38% | 12 qtrssince 2021-Q3 | Increased 57 |
AKERO THERAPEUTICS INC | 5.4M | $127.4M | 2.0% | $24.00 | -2.24% | 3 qtrssince 2023-Q4 | Unchanged 0 |
RTW INVESTMENTS, LP manages $6.5B across 68 positions as of Q2 2024. Top holdings: MDGL (8.3%), RCKT (5.9%), AXSM (5.8%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 7 new positions, 8 exits, 23 increased. Top move: MDGL (INCREASED, conviction 98). Portfolio: $6.5B across 68 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer